NASDAQ:BLUE bluebird bio Q1 2025 Earnings Report $3.49 -0.22 (-5.93%) As of 05/9/2025 03:52 PM Eastern Earnings HistoryForecast bluebird bio EPS ResultsActual EPSN/AConsensus EPS -$2.42Beat/MissN/AOne Year Ago EPSN/Abluebird bio Revenue ResultsActual RevenueN/AExpected Revenue$39.03 millionBeat/MissN/AYoY Revenue GrowthN/Abluebird bio Announcement DetailsQuarterQ1 2025Date5/9/2025TimeN/AConference Call DateThursday, May 15, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile bluebird bio Earnings Headlinesbluebird bio nears acquisition by Carlyle and SK CapitalMay 7 at 1:56 PM | uk.investing.comNew gene therapy considered cure for Sickle Cell Disease being administered at St. Louis Children’s HospitalMay 6, 2025 | msn.comThis robot is coming to 65 million Americans … this year.Robots are the hottest thing going in tech right now. And they just had a coming-out party in Las Vegas. Everywhere you turned at the Consumer Electronics Show, a robot was there to greet you.May 10, 2025 | Weiss Ratings (Ad)Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bioMay 5, 2025 | finance.yahoo.combluebird bio Inc.April 24, 2025 | wsj.comBluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock FellApril 18, 2025 | nasdaq.comSee More bluebird bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like bluebird bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bluebird bio and other key companies, straight to your email. Email Address About bluebird biobluebird bio (NASDAQ:BLUE), a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.View bluebird bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?DexCom Stock: Earnings Beat and New Market Access Drive Bull CaseDisney Stock Jumps on Earnings—Is the Magic Sustainable? Upcoming Earnings Petróleo Brasileiro S.A. - Petrobras (5/12/2025)Simon Property Group (5/12/2025)JD.com (5/13/2025)NU (5/13/2025)SEA (5/13/2025)Sony Group (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Applied Materials (5/15/2025)Copart (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
